Noureddin, Mazen

Publications

Sort by

Co-Author Network

selected publications

Determining Cirrhosis Status in Candidates for Resmetirom. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2025 Editorial Article GET IT
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH. The New England journal of medicine. 2025 Academic Article GET IT
Gaps in MASLD/MASH Education: A Quantitative and Qualitative Survey with Leaders of US Graduate Medical Education Programs. Advances in medical education and practice. 2025 Academic Article GET IT
High Global Prevalence of Steatotic Liver Disease and Associated Subtypes: A Meta-analysis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2025 Review GET IT
Times cited: 1
MetALD: New Perspectives on an Old Overlooked Disease. Liver international : official journal of the International Association for the Study of the Liver. 2025 Review GET IT
Global patterns of utilization of noninvasive tests for the clinical management of metabolic dysfunction-associated steatotic liver disease. Hepatology communications. 2025 Academic Article GET IT
Longitudinal Clinical Outcomes and Mortality from Steatotic Liver Disease: A Meta-Analysis. The American journal of medicine. 2025 Academic Article GET IT
The Emerging Role of Second Harmonic Generation/Two Photon Excitation for Precision Digital Analysis of Liver Fibrosis in MASH Clinical Trials. Journal of hepatology. 2025 Review GET IT
Alcohol-Attributable Cancer: Update From the Global Burden of Disease 2021 Study. Alimentary pharmacology & therapeutics. 2025 Academic Article GET IT
Sex Disparities in Alcohol-Associated Liver Disease and Subtype Differences in Alcohol-attributable Cancers in the United States. Clinical and molecular hepatology. 2025 Academic Article GET IT
Renin-angiotensin-aldosterone system inhibitor use improves clinical outcomes in patients with metabolic dysfunction-associated steatotic liver diseases: Target trial emulation using real-world data. Hepatology (Baltimore, Md.). 2025 Academic Article GET IT
Times cited: 1
Agile 3+ and 4 Scores Accurately Predict Major Adverse Liver Outcomes, Liver Transplant, Progression of MELD Score, the Development of Hepatocellular Carcinoma, and Death in NAFLD. Digestive diseases and sciences. 2025 Academic Article GET IT
Resmetirom: the first approved therapy for treating metabolic dysfunction associated steatohepatitis. Expert opinion on pharmacotherapy. 2025 Review GET IT
The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists. Expert opinion on investigational drugs. 2025 Review GET IT
Times cited: 1
Older adults living with gastrointestinal cancers in 2021. Cancer communications (London, England). 2025 Academic Article GET IT
Early-Onset Gastrointestinal Cancers and Metabolic Risk Factors: Global Trends From the Global Burden of Disease Study 2021. Mayo Clinic proceedings. 2025 Academic Article GET IT
Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000-2021. Clinical and molecular hepatology. 2025 Academic Article GET IT
Mortality of Gastrointestinal Cancers Attributable to Smoking, Alcohol, and Metabolic Risk Factors, and its Association With Socioeconomic Development Status 2000-2021. The American journal of medicine. 2025 Academic Article GET IT
Times cited: 1
Vibration-controlled transient elastography in shaping the epidemiology and management of steatotic liver disease: Editorial on "Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023". Clinical and molecular hepatology. 2024 Editorial Article GET IT
Times cited: 2
Increased mortality from alcohol use disorder, alcohol-associated liver disease, and liver cancer from alcohol among older adults in the United States: 2000 to 2021. Alcohol, clinical & experimental research. 2024 Academic Article GET IT
Global Trend of MASH-associated Liver Cancer: A Systematic Analysis From the Global Burden of Disease 2021. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2024 Academic Article GET IT
Neighborhood Social Determinants of Health are Associated With Metabolic Dysfunction-associated Steatotic Liver Disease Outcomes. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2024 Academic Article GET IT
Metabolic issues in patients with metabolic dysfunction-associated steatohepatitis (MASH) and their impact on MASH recurrence following liver transplantation: A narrative review. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2024 Academic Article GET IT
Alcohol-related liver and extrahepatic malignancies: burden of disease and socioeconomic disparities in 2019. European journal of gastroenterology & hepatology. 2024 Academic Article GET IT
The burden of alcohol and substance use disorders in adolescents and young adults. Drug and alcohol dependence. 2024 Academic Article GET IT
Times cited: 3
Management strategies for metabolic dysfunction-associated steatotic liver disease (MASLD). The American journal of managed care. 2024 Review GET IT
Times cited: 4
Noninvasive Assessment to Identify Patients With At-Risk Metabolic Dysfunction-Associated Steatohepatitis. Gastroenterology & hepatology. 2024 Academic Article GET IT
Reply. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2024 Letter GET IT
Disparities in steatosis prevalence in the United States by Race or Ethnicity according to the 2023 criteria. Communications medicine. 2024 Academic Article GET IT
Times cited: 3
Letter to the Editor: Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF). Hepatology (Baltimore, Md.). 2024 Academic Article GET IT
Prevalence and longitudinal effects on mortality associated with spectrum of alcohol intake in steatotic liver disease: a United States population study. Hepatobiliary surgery and nutrition. 2024 Academic Article GET IT
Mortality outcomes in individuals with MASLD versus MASLD and increased alcohol intake. Journal of gastroenterology and hepatology. 2024 Academic Article GET IT
Times cited: 11
Deploying a metabolic dysfunction-associated steatohepatitis consensus care pathway: findings from an educational pilot in three health systems. BMC primary care. 2024 Academic Article GET IT
Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2024 Review GET IT
Times cited: 30
Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: Systematic review and network meta-analysis. Hepatology (Baltimore, Md.). 2024 Academic Article GET IT
Times cited: 7
Global Prevalence, Clinical Characteristics, Surveillance, Treatment Allocation, and Outcomes of Alcohol-Associated Hepatocellular Carcinoma. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2024 Review GET IT
Times cited: 16
The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD)-related advanced fibrosis and cirrhosis in the United States population utilizing AGILE 3 + and AGILE 4 scores: analysis of the NHANES 2017-2018 cycle. BMC gastroenterology. 2024 Academic Article GET IT
Times cited: 1
Sex and Race-Ethnic Disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease: An Analysis of 40,166 Individuals. Digestive diseases and sciences. 2024 Academic Article GET IT
Times cited: 5
Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019. Metabolism: clinical and experimental. 2024 Academic Article GET IT
Times cited: 28
Sex-based Disparities in Liver Transplantation for Hepatocellular Carcinoma and the Impact of the Growing Burden of NASH. Transplantation direct. 2024 Academic Article GET IT
Times cited: 1
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis. Journal of hepatology. 2024 Academic Article GET IT
Times cited: 16
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. The New England journal of medicine. 2024 Academic Article GET IT
Times cited: 128
Global epidemiology of alcohol-associated liver disease in adolescents and young adults. Alimentary pharmacology & therapeutics. 2024 Academic Article GET IT
Times cited: 16
Diagnosis and non-invasive assessment of MASLD in type 2 diabetes and obesity. Alimentary pharmacology & therapeutics. 2024 Review GET IT
Times cited: 9
Socio-economic association of alcohol use disorder and cardiovascular and alcohol-associated liver disease from 2010 to 2019. Alimentary pharmacology & therapeutics. 2024 Academic Article GET IT
Times cited: 17
Combination Treatment in MASLD: The Next Frontier. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2024 Editorial Article GET IT
Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting. Postgraduate medicine. 2024 Review GET IT
Times cited: 6
MASLD/MetALD and mortality in individuals with any cardio-metabolic risk factor: A population-based study with 26.7 years of follow-up. Hepatology (Baltimore, Md.). 2024 Academic Article GET IT
Times cited: 21
The Burden of Overweight and Obesity-Associated Gastrointestinal Cancers in Low and Lower-Middle-Income Countries: A Global Burden of Disease 2019 Analysis. The American journal of gastroenterology. 2024 Academic Article GET IT
Times cited: 21
Use of non-invasive diagnostic tools for metabolic dysfunction-associated steatohepatitis: A qualitative exploration of challenges and barriers. Liver international : official journal of the International Association for the Study of the Liver. 2024 Academic Article GET IT
Times cited: 7
Incidence of liver cancer in young adults according to the Global Burden of Disease database 2019. Hepatology (Baltimore, Md.). 2024 Academic Article GET IT
Times cited: 24
Diagnostic accuracy of non-invasive tests to screen for at-risk MASH-An individual participant data meta-analysis. Liver international : official journal of the International Association for the Study of the Liver. 2024 Review GET IT
Times cited: 8
Metabolic Syndrome and Metabolic Dysfunction-Associated Steatotic Liver Disease in Premenopausal Women: Global Trends and Projections to 2040. Mayo Clinic proceedings. 2024 Academic Article GET IT
Times cited: 14
MASH clinical trials and drugs pipeline: An impending tsunami. Hepatology (Baltimore, Md.). 2024 Academic Article GET IT
Times cited: 16
Degree of Discordance Between FIB-4 and Transient Elastography: An Application of Current Guidelines on General Population Cohort. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2024 Academic Article GET IT
Times cited: 13
The Global Burden of Alcohol-associated Cirrhosis and Cancer in Young and Middle-aged Adults. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2024 Academic Article GET IT
Times cited: 17
Artificial intelligence in liver cancer research: a scientometrics analysis of trends and topics. Frontiers in oncology. 2024 Academic Article GET IT
Times cited: 1
Reply. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2024 Letter GET IT
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. The New England journal of medicine. 2024 Academic Article GET IT
Times cited: 445
From Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Steatotic Liver Disease: Out with the Old, in with the New. Journal of clinical medicine. 2024 Editorial Article GET IT
Times cited: 3
Meta-analysis: Prevalence and impact of alcohol abstinence in alcohol-associated cirrhosis. Alimentary pharmacology & therapeutics. 2024 Review GET IT
Times cited: 10
Uncoupler therapy for NAFLD: is flushing a possible harbinger of a safety concern? - Authors' reply. The lancet. Gastroenterology & hepatology. 2024 Letter GET IT
Global and regional burden of alcohol-associated liver disease and alcohol use disorder in the elderly. JHEP reports : innovation in hepatology. 2024 Academic Article GET IT
Times cited: 10
From Shadows to Spotlight: Exploring the Escalating Burden of Alcohol-Associated Liver Disease and Alcohol Use Disorder in Young Women. The American journal of gastroenterology. 2024 Academic Article GET IT
Times cited: 17
A scientifically validated combination of garcinol, curcuminoids, and piperine for mild to moderate nonalcoholic steatohepatitis patients-results from a randomized, double-blind, placebo-controlled study. Frontiers in nutrition. 2023 Academic Article GET IT
Times cited: 1
The Global Burden of Early-Onset Biliary Tract Cancer: Insight From the Global Burden of Disease Study 2019. Journal of clinical and experimental hepatology. 2023 Academic Article GET IT
Times cited: 8
COVID-19 Pandemic Impact on Diagnosis, Stage, and Treatment of Hepatocellular Carcinoma in the United States. Gastro hep advances. 2023 Academic Article GET IT
Times cited: 1
Proton Pump Inhibitors Increases Longitudinal Risk of Mortality, Decompensation, and Infection in Cirrhosis: A Meta-Analysis. Digestive diseases and sciences. 2023 Review GET IT
Times cited: 11
Transplant Oncology: An Emerging Discipline of Cancer Treatment. Cancers. 2023 Review GET IT
Times cited: 15
Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2023 Academic Article GET IT
Times cited: 75
Embracing Change: From Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Steatotic Liver Disease Under the Steatotic Liver Disease Umbrella. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2023 Editorial Article GET IT
Times cited: 4
Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial. The lancet. Gastroenterology & hepatology. 2023 Academic Article GET IT
Times cited: 21
Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. Alimentary pharmacology & therapeutics. 2023 Academic Article GET IT
Times cited: 45
A Novel Prescription Digital Therapeutic Option for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease. Gastro hep advances. 2023 Academic Article GET IT
Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2023 Review GET IT
Times cited: 44
Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective. Journal of clinical medicine. 2023 Review GET IT
Times cited: 13
The silent burden of non-alcoholic fatty liver disease in the elderly: A global burden of disease analysis. Alimentary pharmacology & therapeutics. 2023 Academic Article GET IT
Times cited: 21
Utilization of Noninvasive Tests to Diagnose At-Risk Metabolic Dysfunction-Associated Steatohepatitis. Gastroenterology & hepatology. 2023 Academic Article GET IT
Immunotherapy and Transarterial Radioembolization Combination Treatment for Advanced Hepatocellular Carcinoma. The American journal of gastroenterology. 2023 Academic Article GET IT
Times cited: 11
A global action agenda for turning the tide on fatty liver disease. Hepatology (Baltimore, Md.). 2023 Academic Article GET IT
Times cited: 42
Learnings From the Graveyard of Phase 2 and 3 Nonalcoholic Steatohepatitis Trials. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2023 Editorial Article GET IT
Times cited: 4
Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF). Hepatology (Baltimore, Md.). 2023 Academic Article GET IT
Times cited: 37
Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis. The lancet. Gastroenterology & hepatology. 2023 Review GET IT
Times cited: 78
Caring for the Liver: Updates on Global Prevalence, Cutting-Edge Diagnosis, and State-of-the-Art Management for Researchers and Clinicians, 2023 and Beyond. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2023 Academic Article GET IT
Times cited: 1
Noninvasive tests in the evaluation of nonalcoholic fatty liver disease: A review. Clinical liver disease. 2023 Review GET IT
Times cited: 2
A global research priority agenda to advance public health responses to fatty liver disease. Journal of hepatology. 2023 Academic Article GET IT
Times cited: 66
Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. The lancet. Gastroenterology & hepatology. 2023 Review GET IT
Times cited: 111
Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis. International journal of obesity (2005). 2023 Review GET IT
Times cited: 36
Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study. Hepatology (Baltimore, Md.). 2023 Academic Article GET IT
Times cited: 14
Prediagnostic CT or MRI Utilization and Outcomes in Hepatocellular Carcinoma: SEER-Medicare Database Analysis. Cancer research communications. 2023 Academic Article GET IT
Times cited: 2
Extracellular vesicles in fatty liver promote a metastatic tumor microenvironment. Cell metabolism. 2023 Academic Article GET IT
Times cited: 92
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study. Hepatology (Baltimore, Md.). 2023 Academic Article GET IT
Times cited: 34
Increased accuracy in identifying NAFLD with advanced fibrosis and cirrhosis: independent validation of the Agile 3+ and 4 scores. Hepatology communications. 2023 Academic Article GET IT
Times cited: 21
An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography. Journal of hepatology. 2023 Review GET IT
Times cited: 42
Clinical Trial Landscape in NASH. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2023 Review GET IT
Times cited: 71
Ethnic disparities in waitlist outcomes of patients with nonalcoholic steatohepatitis listed for liver transplantation in the US. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2023 Academic Article GET IT
Times cited: 5
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future. Clinical and molecular hepatology. 2023 Editorial Article GET IT
Times cited: 2
A proposal from the liver forum for the management of comorbidities in non-alcoholic steatohepatitis therapeutic trials. Journal of hepatology. 2023 Review GET IT
Times cited: 10
The use of current knowledge and non-invasive testing modalities for predicting at-risk non-alcoholic steatohepatitis and assessing fibrosis. Liver international : official journal of the International Association for the Study of the Liver. 2023 Review GET IT
Times cited: 12
Challenges and opportunities in NASH drug development. Nature medicine. 2023 Review GET IT
Times cited: 195
The global burden of metabolic disease: Data from 2000 to 2019. Cell metabolism. 2023 Academic Article GET IT
Times cited: 370
Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis. Journal of clinical gastroenterology. 2023 Academic Article GET IT
Times cited: 3
Current Treatment Options, Including Diet, Exercise, and Medications: The Impact on Histology. Clinics in liver disease. 2023 Review GET IT
Times cited: 5
MRI-AST (MAST) Score Accurately Predicts Major Adverse Liver Outcome, Hepatocellular Carcinoma, Liver Transplant, and Liver-Related Death. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2023 Academic Article GET IT
Times cited: 24
HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma. Hepatology (Baltimore, Md.). 2023 Academic Article GET IT
Times cited: 58
Treatment of Cushing Disease With Pituitary-Targeting Seliciclib. The Journal of clinical endocrinology and metabolism. 2023 Academic Article GET IT
Times cited: 21
Safety and tolerability of obeticholic acid in chronic liver disease: a pooled analysis of 1878 individuals. Hepatology communications. 2023 Academic Article GET IT
Times cited: 19
Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma. Clinical and molecular hepatology. 2023 Academic Article GET IT
Times cited: 6
The prognostic value of including non-alcoholic fatty liver disease in the definition of metabolic syndrome. Alimentary pharmacology & therapeutics. 2023 Academic Article GET IT
Times cited: 16
The global syndemic of metabolic diseases in the young adult population: A consortium of trends and projections from the Global Burden of Disease 2000-2019. Metabolism: clinical and experimental. 2023 Academic Article GET IT
Times cited: 92
Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis. Alimentary pharmacology & therapeutics. 2023 Academic Article GET IT
Times cited: 12
Hyperphosphorylation of hepatic proteome characterizes nonalcoholic fatty liver disease in S-adenosylmethionine deficiency. iScience. 2023 Academic Article GET IT
Times cited: 1
Examining the interim proposal for name change to steatotic liver disease in the US population. Hepatology (Baltimore, Md.). 2023 Academic Article GET IT
Times cited: 10
Reply: Machine learning models for NAFLD/NASH and cirrhosis diagnosis and staging: accuracy and routine variables are the success keys. Hepatology (Baltimore, Md.). 2023 Letter GET IT
Times cited: 1
Diabetes and Risk of Hepatocellular Carcinoma in Cirrhosis Patients with Nonalcoholic Fatty Liver Disease. Gut and liver. 2022 Review GET IT
Times cited: 13
A practical use of noninvasive tests in clinical practice to identify high-risk patients with nonalcoholic steatohepatitis. Alimentary pharmacology & therapeutics. 2022 Academic Article GET IT
Times cited: 29
MAFLD vs. NAFLD not an emotional political process - rather Evidence-Based Medicine. Annals of hepatology. 2022 Letter GET IT
Hepatic, Extra-hepatic Outcomes and Causes of Mortality in NAFLD - An Umbrella Overview of Systematic Review of Meta-Analysis. Journal of clinical and experimental hepatology. 2022 Review GET IT
Times cited: 21
Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. The lancet. Gastroenterology & hepatology. 2022 Review GET IT
Times cited: 323
Reply. Gastroenterology. 2022 Letter GET IT
MEFIB vs. MAST and FAST: Not a competition but useful tools. Journal of hepatology. 2022 Letter GET IT
Times cited: 5
NASH cirrhosis trials and major adverse liver outcomes: Big data needed. Journal of hepatology. 2022 Editorial Article GET IT
Times cited: 4
DEXA Scan Body Fat Mass Distribution in Obese and Non-Obese Individuals and Risk of NAFLD-Analysis of 10,865 Individuals. Journal of clinical medicine. 2022 Academic Article GET IT
Times cited: 1
A Meta-analysis on Associated Risk of Mortality in Nonalcoholic Fatty Liver Disease. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2022 Review GET IT
Times cited: 23
Cardiovascular and hepatic disease associations by magnetic resonance imaging: A retrospective cohort study. Frontiers in cardiovascular medicine. 2022 Academic Article GET IT
Depression in non-alcoholic fatty liver disease is associated with an increased risk of complications and mortality. Frontiers in medicine. 2022 Academic Article GET IT
Times cited: 10
The Spectrum and Impact of Metabolic Dysfunction in MAFLD: A Longitudinal Cohort Analysis of 32,683 Overweight and Obese Individuals. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2022 Academic Article GET IT
Times cited: 19
Placebo Adverse Events in Non-alcoholic Steatohepatitis Clinical Trials: A Pooled Analysis of 2,944 Participants. The American journal of gastroenterology. 2022 Review GET IT
Times cited: 8
The placebo response rate and nocebo events in obesity pharmacological trials. A systematic review and meta-analysis. EClinicalMedicine. 2022 Academic Article GET IT
Times cited: 20
Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis. Annals of hepatology. 2022 Academic Article GET IT
Times cited: 31
A poor perspective of self weight significantly increases adverse outcomes in non-alcoholic fatty liver disease (NAFLD). Frontiers in medicine. 2022 Academic Article GET IT
Times cited: 5
Statins decrease overall mortality and cancer related mortality but are underutilized in NAFLD: a longitudinal analysis of 12,538 individuals. Expert review of gastroenterology & hepatology. 2022 Academic Article GET IT
Times cited: 13
Longitudinal Assessment of Bile Duct Loss in Primary Biliary Cholangitis. The American journal of gastroenterology. 2022 Academic Article GET IT
Times cited: 2
Nonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers. Mayo Clinic proceedings. 2022 Review GET IT
Times cited: 32
A Revisit of the Natural History of Nonalcoholic Fatty Liver Disease. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2022 Editorial Article GET IT
Times cited: 1
Simple diagnostic algorithm identifying at-risk nonalcoholic fatty liver disease patients needing specialty referral within the United States. World journal of hepatology. 2022 Academic Article GET IT
Times cited: 2
Disparities in curative treatments and outcomes for early stage intrahepatic cholangiocarcinoma in the United States. Cancer. 2022 Academic Article GET IT
Times cited: 8
Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A Meta-Analysis and Systematic Review of 10 739 607 Individuals. The Journal of clinical endocrinology and metabolism. 2022 Review GET IT
Times cited: 186
Complete alcohol abstinence increases the risk of NAFLD but not severity. A population analysis with transient elastography. Scandinavian journal of gastroenterology. 2022 Academic Article GET IT
Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis. Hepatology (Baltimore, Md.). 2022 Academic Article GET IT
Times cited: 39
Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality. Frontiers in cardiovascular medicine. 2022 Academic Article GET IT
Times cited: 39
FIB-4 Predicts MACE and Cardiovascular Mortality in Patients With Nonalcoholic Fatty Liver Disease. The Canadian journal of cardiology. 2022 Letter GET IT
Times cited: 21
The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database. BMC gastroenterology. 2022 Academic Article GET IT
Times cited: 27
Improvement in nonalcoholic fatty liver disease through bariatric surgery. Clinical liver disease. 2022 Review GET IT
Times cited: 5
Comparative Burden of Metabolic Dysfunction in Lean NAFLD vs Non-lean NAFLD - A Systematic Review and Meta-analysis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2022 Review GET IT
Times cited: 67
IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH. Hepatology (Baltimore, Md.). 2022 Academic Article GET IT
Times cited: 21
AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review. Gastroenterology. 2022 Guideline GET IT
Times cited: 182
Living in the non-alcoholic fatty liver disease silent epidemic: a qualitative systematic review of patients' perspectives. Alimentary pharmacology & therapeutics. 2022 Review GET IT
Times cited: 13
Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants. Gastroenterology. 2022 Review GET IT
Times cited: 94
Foregut bypass vs. restrictive bariatric procedures for nonalcoholic fatty liver disease: a meta-analysis of 3,355 individuals. Hepatobiliary surgery and nutrition. 2022 Academic Article GET IT
Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update. Seminars in liver disease. 2022 Review GET IT
Times cited: 27
A Class Effect Network Meta-analysis of Lipid Modulation in Non-alcoholic Steatohepatitis for Dyslipidemia. Journal of clinical and translational hepatology. 2022 Academic Article GET IT
Times cited: 4
Predictive and Prognostic Roles of Gut Microbial Variation in Liver Transplant. Frontiers in medicine. 2022 Review GET IT
Times cited: 6
Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017-2018. Hepatology communications. 2022 Academic Article GET IT
Times cited: 23
Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States. Hepatology (Baltimore, Md.). 2022 Academic Article GET IT
Times cited: 31
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. Journal of hepatology. 2022 Academic Article GET IT
Times cited: 144
Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. Hepatology (Baltimore, Md.). 2022 Academic Article GET IT
Times cited: 29
Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017-2018 transient elastography data and application of machine learning. Hepatology communications. 2022 Academic Article GET IT
Times cited: 54
The Interplay Between Nonalcoholic Fatty Liver Disease and Kidney Disease. Clinics in liver disease. 2022 Review GET IT
Times cited: 9
Metabolic Associated Fatty Liver Disease Increases the Risk of Systemic Complications and Mortality. A Meta-Analysis and Systematic Review of 12 620 736 Individuals. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2022 Review GET IT
Times cited: 52
Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis. Hepatology international. 2022 Review GET IT
Times cited: 35
Clinical Characteristics and Outcomes of Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in the United States. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2022 Academic Article GET IT
Times cited: 45
Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. Hepatology (Baltimore, Md.). 2022 Academic Article GET IT
Times cited: 41
Meta-analysis: analysis of mechanistic pathways in the treatment of non-alcoholic steatohepatitis. Evidence from a Bayesian network meta-analysis. Alimentary pharmacology & therapeutics. 2022 Review GET IT
Times cited: 19
Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know. Alimentary pharmacology & therapeutics. 2022 Review GET IT
Times cited: 29
ACE inhibitors: The secret to prevent cirrhosis complications and HCC in NAFLD?. Hepatology (Baltimore, Md.). 2022 Editorial Article GET IT
Times cited: 4
The impact of COVID-19 on the cascade of care of HCV in the US and China. Annals of hepatology. 2022 Academic Article GET IT
Times cited: 16
UNOS Down-Staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of 25 Studies. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2022 Review GET IT
Times cited: 42
Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials. Expert opinion on investigational drugs. 2022 Academic Article GET IT
Times cited: 8
Subclinical hepatic fibrosis is associated with coronary microvascular dysfunction by myocardial perfusion reserve index: a retrospective cohort study. The international journal of cardiovascular imaging. 2022 Academic Article GET IT
Placebo effect on progression and regression in NASH: Evidence from a meta-analysis. Hepatology (Baltimore, Md.). 2022 Review GET IT
Times cited: 53
Lifestyle and Hepatocellular Carcinoma What Is the Evidence and Prevention Recommendations. Cancers. 2021 Review GET IT
Times cited: 20
S-adenosylmethionine inhibits la ribonucleoprotein domain family member 1 in murine liver and human liver cancer cells. Hepatology (Baltimore, Md.). 2021 Academic Article GET IT
Times cited: 22
Why are there no strategies for NAFLD?. Journal of hepatology. 2021 Editorial Article GET IT
Times cited: 3
An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2021 Review GET IT
Times cited: 156
A Diagnostic Test Meta-Analysis Evaluating Imaging-Based and Blood Biomarker-Based Assessment Tools for Fibrosis After Liver Transplantation. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2021 Review GET IT
Times cited: 8
Current and Potential Therapies Targeting Inflammation in NASH. Frontiers in endocrinology. 2021 Review GET IT
Times cited: 28
Routine Versus Selective Liver Biopsy During Bariatric Surgery: Postoperative Outcomes and Preoperative Predictors of NASH. Obesity surgery. 2021 Academic Article GET IT
Times cited: 2
Duodenal Microbiome and Serum Metabolites Predict Hepatocellular Carcinoma in a Multicenter Cohort of Patients with Cirrhosis. Digestive diseases and sciences. 2021 Academic Article GET IT
Times cited: 11
Outcomes of Nonalcoholic Steatohepatitis After Liver Transplantation: An Updated Meta-Analysis and Systematic Review. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2021 Review GET IT
Times cited: 35
MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis. Journal of hepatology. 2021 Academic Article GET IT
Times cited: 127
A Meta-Analysis and Systematic Review on the Global Prevalence, Risk Factors, and Outcomes of Coronary Artery Disease in Liver Transplantation Recipients. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2021 Review GET IT
Times cited: 22
The Mortality and Overall Survival Trends of Primary Liver Cancer in the United States. Journal of the National Cancer Institute. 2021 Academic Article GET IT
Times cited: 61
Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2021 Review GET IT
Times cited: 80
Magnetic Resonance Elastography as a Predictor of Response to Therapy in Patients With Nonalcoholic Steatohepatitis. Gastroenterology & hepatology. 2021 Academic Article GET IT
Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States. Hepatology (Baltimore, Md.). 2021 Academic Article GET IT
Times cited: 48
Population-based return on investment of deploying transient elastography. The American journal of managed care. 2021 Academic Article GET IT
Times cited: 4
R. Magnetic resonance in medicine. 2021 Academic Article GET IT
Times cited: 28
Application of Artificial Intelligence for Diagnosis and Risk Stratification in NAFLD and NASH: The State of the Art. Hepatology (Baltimore, Md.). 2021 Review GET IT
Times cited: 33
Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology (Baltimore, Md.). 2021 Academic Article GET IT
Times cited: 260
Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2021 Academic Article GET IT
Times cited: 72
Association of Genetic Risk Score With NAFLD in An Ethnically Diverse Cohort. Hepatology communications. 2021 Academic Article GET IT
Times cited: 30
Incidence of Complications from Percutaneous Biopsy in Chronic Liver Disease: A Systematic Review and Meta-Analysis. Digestive diseases and sciences. 2021 Review GET IT
Times cited: 65
State-Level HCC Incidence and Association With Obesity and Physical Activity in the United States. Hepatology (Baltimore, Md.). 2021 Academic Article GET IT
Times cited: 28
Racial and ethnic disparities in non-alcoholic fatty liver disease in the USA. The lancet. Gastroenterology & hepatology. 2021 Academic Article GET IT
Times cited: 22
Artificial Intelligence in NASH Histology: Human Teaches a Machine for the Machine to Help Humans. Hepatology (Baltimore, Md.). 2021 Editorial Article GET IT
Times cited: 7
Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. Hepatology communications. 2021 Academic Article GET IT
Times cited: 27
Comparison of Surgical Resection and Systemic Treatment for Hepatocellular Carcinoma with Vascular Invasion: National Cancer Database Analysis. Liver cancer. 2021 Academic Article GET IT
Times cited: 31
Progression of Nonalcoholic Fatty Liver Disease-Associated Fibrosis in a Large Cohort of Patients with Type 2 Diabetes. Digestive diseases and sciences. 2021 Academic Article GET IT
Times cited: 18
Acute on Chronic Liver Failure From Nonalcoholic Fatty Liver Disease: A Growing and Aging Cohort With Rising Mortality. Hepatology (Baltimore, Md.). 2021 Academic Article GET IT
Times cited: 34
Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis. Expert review of clinical pharmacology. 2021 Review GET IT
Times cited: 36
Noninvasive Evaluation for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clinical therapeutics. 2021 Review GET IT
Times cited: 14
Therapeutic pipeline in nonalcoholic steatohepatitis. Nature reviews. Gastroenterology & hepatology. 2021 Review GET IT
Times cited: 225
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH. Hepatology (Baltimore, Md.). 2021 Academic Article GET IT
Times cited: 211
Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. The American journal of gastroenterology. 2021 Review GET IT
Times cited: 79
Estrogen-Driven Growth of Focal Nodular Hyperplasia: Truth or Myth? 2021 GET IT
Sex differences in age at wait-list registration for liver transplantation with nonalcoholic steatohepatitis as primary indication. Clinical transplantation. 2020 Letter GET IT
Driving Nonalcoholic Steatohepatitis Forward Using the FibroScan Aspartate Aminotransferase Score, But Obey the Traffic Lights. Hepatology (Baltimore, Md.). 2020 Comment GET IT
Times cited: 13
Liver Injury Impaired 25-Hydroxylation of Vitamin D Suppresses Intestinal Paneth Cell defensins, leading to Gut Dysbiosis and Liver Fibrogenesis. American journal of physiology. Gastrointestinal and liver physiology. 2020 Academic Article GET IT
Times cited: 20
Increase in Alcoholic Hepatitis as an Etiology for Liver Transplantation in the United States: A 2004-2018 Analysis. Transplantation direct. 2020 Academic Article GET IT
Times cited: 4
Association of State Medicaid Expansion With Racial/Ethnic Disparities in Liver Transplant Wait-listing in the United States. JAMA network open. 2020 Academic Article GET IT
Times cited: 32
Factors Associated With Detection and Survival of T1 Hepatocellular Carcinoma in the United States: National Cancer Database Analysis. Journal of the National Comprehensive Cancer Network : JNCCN. 2020 Academic Article GET IT
Times cited: 5
Associations Between Reproductive and Hormone-Related Factors and Risk of Nonalcoholic Fatty Liver Disease in a Multiethnic Population. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2020 Academic Article GET IT
Times cited: 33
Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis. Gastroenterology. 2020 Academic Article GET IT
Times cited: 93
Clinical considerations in the management of non-alcoholic steatohepatitis cirrhosis pre- and post-transplant: A multi-system challenge. World journal of gastroenterology. 2020 Review GET IT
Times cited: 4
MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study. Liver international : official journal of the International Association for the Study of the Liver. 2020 Academic Article GET IT
Times cited: 62
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial. Hepatology (Baltimore, Md.). 2020 Academic Article GET IT
Times cited: 270
Current Understanding of Risk for Nonalcoholic Steatohepatitis and Progressive Fibrosis. Gastroenterology & hepatology. 2020 Academic Article GET IT
Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. Alimentary pharmacology & therapeutics. 2020 Review GET IT
Times cited: 73
Dietary Protein, Fiber and Coffee Are Associated with Small Intestine Microbiome Composition and Diversity in Patients with Liver Cirrhosis. Nutrients. 2020 Academic Article GET IT
Times cited: 19
STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus. Journal of hepatology. 2020 Editorial Article GET IT
Times cited: 26
Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum. Gastroenterology. 2020 Editorial Article GET IT
Times cited: 19
Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum. Journal of hepatology. 2020 Review GET IT
Times cited: 71
Higher thresholds for the utilization of steatotic allografts in liver transplantation: Analysis from a U.S. national database. PloS one. 2020 Academic Article GET IT
Times cited: 16
Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review. World journal of hepatology. 2020 Academic Article GET IT
Times cited: 21
Diet Quality Association with Nonalcoholic Fatty Liver Disease by Cirrhosis Status: The Multiethnic Cohort. Current developments in nutrition. 2020 Academic Article GET IT
Times cited: 34
Diet Associations With Nonalcoholic Fatty Liver Disease in an Ethnically Diverse Population: The Multiethnic Cohort. Hepatology (Baltimore, Md.). 2020 Academic Article GET IT
Times cited: 104
Noninvasive Testing Using Magnetic Resonance Imaging Techniques as Outcomes in Nonalcoholic Steatohepatitis Clinical Trials: How Full Is the Glass?. Hepatology communications. 2020 Academic Article GET IT
Times cited: 14
Vitamin D signaling maintains intestinal innate immunity and gut microbiota: potential intervention for metabolic syndrome and NAFLD. American journal of physiology. Gastrointestinal and liver physiology. 2020 Academic Article GET IT
Times cited: 38
Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)?. Expert opinion on investigational drugs. 2020 Review GET IT
Times cited: 29
Drug discovery and treatment paradigms in nonalcoholic steatohepatitis. Endocrinology, diabetes & metabolism. 2019 Review GET IT
Times cited: 36
Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. Gastroenterology. 2019 Academic Article GET IT
Times cited: 259
Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort. World journal of hepatology. 2019 Academic Article GET IT
Times cited: 11
Fibrosis Changes in the Placebo Arm of NASH Clinical Trials. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2019 Letter GET IT
Times cited: 3
GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH). Expert opinion on investigational drugs. 2019 Review GET IT
Times cited: 121
Screening for Nonalcoholic Fatty Liver Disease in the Primary Care Clinic. Gastroenterology & hepatology. 2019 Academic Article GET IT
Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease. World journal of gastroenterology. 2019 Review GET IT
Times cited: 159
Hyaluronan synthase 2-mediated hyaluronan production mediates Notch1 activation and liver fibrosis. Science translational medicine. 2019 Academic Article GET IT
Times cited: 116
Awareness of Nonalcoholic Fatty Liver Disease Is Increasing but Remains Very Low in a Representative US Cohort. Digestive diseases and sciences. 2019 Academic Article GET IT
Times cited: 39
Looking Into the Crystal Ball: Predicting the Future Challenges of Fibrotic NASH Treatment. Hepatology communications. 2019 Review GET IT
Times cited: 14
Gα12 ablation exacerbates liver steatosis and obesity by suppressing USP22/SIRT1-regulated mitochondrial respiration. The Journal of clinical investigation. 2018 Academic Article GET IT
Times cited: 48
Pathogenesis of NASH: The Impact of Multiple Pathways. Current hepatology reports. 2018 Academic Article GET IT
Times cited: 94
Liver Transplantation for Severe Alcoholic Hepatitis: Report of a Single Center Pilot Program. Transplantation proceedings. 2018 Academic Article GET IT
Times cited: 11
Editorial: role of leucine-metformin-sildenafil combination in the treatment of nonalcoholic fatty liver disease (NAFLD). Alimentary pharmacology & therapeutics. 2018 Editorial Article GET IT
Microbiome and bile acid profiles in duodenal aspirates from patients with liver cirrhosis: The Microbiome, Microbial Markers and Liver Disease Study. Hepatology research : the official journal of the Japan Society of Hepatology. 2018 Academic Article GET IT
Times cited: 27
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2018 Academic Article GET IT
Times cited: 284
Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2018 Review GET IT
Times cited: 107
NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances. The American journal of gastroenterology. 2018 Academic Article GET IT
Times cited: 466
Mechanisms of MAFG Dysregulation in Cholestatic Liver Injury and Development of Liver Cancer. Gastroenterology. 2018 Academic Article GET IT
Times cited: 74
Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts. Hepatology communications. 2018 Academic Article GET IT
Times cited: 131
Class III obesity is a risk factor for the development of acute-on-chronic liver failure in patients with decompensated cirrhosis. Journal of hepatology. 2018 Academic Article GET IT
Times cited: 66
Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals. World journal of gastroenterology. 2018 Academic Article GET IT
Times cited: 64
Insulin signaling as a potential natural killer cell checkpoint in fatty liver disease. Hepatology communications. 2018 Academic Article GET IT
Times cited: 28
Role of Aramchol in steatohepatitis and fibrosis in mice. Hepatology communications. 2017 Academic Article GET IT
Times cited: 93
The role of bariatric surgery in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Expert review of gastroenterology & hepatology. 2017 Review GET IT
Times cited: 28
Coffee Drinking and Alcoholic and Nonalcoholic Fatty Liver Diseases and Viral Hepatitis in the Multiethnic Cohort. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2017 Academic Article GET IT
Times cited: 18
Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD). Expert review of clinical pharmacology. 2017 Review GET IT
Times cited: 33
Prohibitin 1 suppresses liver cancer tumorigenesis in mice and human hepatocellular and cholangiocarcinoma cells. Hepatology (Baltimore, Md.). 2017 Academic Article GET IT
Times cited: 46
Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis. Gastroenterology. 2017 Academic Article GET IT
Times cited: 222
Predictors of Mortality in the Critically Ill Cirrhotic Patient: Is the Model for End-Stage Liver Disease Enough?. Journal of the American College of Surgeons. 2016 Academic Article GET IT
Times cited: 16
Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis. Alimentary pharmacology & therapeutics. 2016 Academic Article GET IT
Times cited: 142
Promising therapies for treatment of nonalcoholic steatohepatitis. Expert opinion on emerging drugs. 2016 Review GET IT
Times cited: 29
Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort. Hepatology (Baltimore, Md.). 2016 Academic Article GET IT
Times cited: 243
Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis. Alimentary pharmacology & therapeutics. 2016 Review GET IT
Times cited: 42
The Significance of Autoantibody Changes Over Time in Primary Biliary Cirrhosis. American journal of clinical pathology. 2015 Academic Article GET IT
Times cited: 34
Sofosbuvir and Simeprevir Therapy for Recurrent Hepatitis C Infection After Liver Transplantation. Transplantation direct. 2015 Academic Article GET IT
Times cited: 10
Hepatic expression levels of interferons and interferon-stimulated genes in patients with chronic hepatitis C: A phenotype-genotype correlation study. Genes and immunity. 2015 Academic Article GET IT
Times cited: 26
Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. Experimental biology and medicine (Maywood, N.J.). 2015 Review GET IT
Times cited: 96
MRI, CT scan, and ultrasound in the diagnosis of nonalcoholic fatty liver disease. Journal of clinical gastroenterology. 2015 Letter GET IT
Times cited: 7
Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Clinics in liver disease. 2015 Review GET IT
Times cited: 155
Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology (Baltimore, Md.). 2015 Academic Article GET IT
Times cited: 309
Ribavirin improves the IFN-γ response of natural killer cells to IFN-based therapy of hepatitis C virus infection. Hepatology (Baltimore, Md.). 2014 Academic Article GET IT
Times cited: 26
Reply: To PMID 23703931. Hepatology (Baltimore, Md.). 2014 Letter GET IT
Hepatitis delta: epidemiology, diagnosis and management 36 years after discovery. Current gastroenterology reports. 2014 Review GET IT
Times cited: 89
Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology (Baltimore, Md.). 2013 Academic Article GET IT
Times cited: 471
Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology (Baltimore, Md.). 2013 Academic Article GET IT
Times cited: 163
Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology (Baltimore, Md.). 2013 Academic Article GET IT
Times cited: 98
Temperature rise after peginterferon alfa-2a injection in patients with chronic hepatitis C is associated with virological response and is modulated by IL28B genotype. Journal of hepatology. 2013 Academic Article GET IT
Times cited: 4
Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut. 2013 Academic Article GET IT
Times cited: 46
Nonalcoholic fatty liver disease: Indications for liver biopsy and noninvasive biomarkers. Clinical liver disease. 2012 Review GET IT
HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology. 2012 Academic Article GET IT
Times cited: 241
Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. Hepatology (Baltimore, Md.). 2011 Academic Article GET IT
Times cited: 97
Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology. 2011 Academic Article GET IT
Times cited: 139
Editorial: Treatment of patients with HCV-related cirrhosis with peginterferon and ribavirin: Swinging the pendulum toward treatment. The American journal of gastroenterology. 2010 Editorial Article GET IT
Times cited: 3
To resect or not to resect? That is the question. Telangiectatic adenoma. 2010 GET IT
Pharmacokinetics and pharmacodynamics of peginterferon and ribavirin: implications for clinical efficacy in the treatment of chronic hepatitis C. Gastroenterology clinics of North America. 2010 Review GET IT
Times cited: 23
Changes in S-adenosylmethionine and GSH homeostasis during endotoxemia in mice. Laboratory investigation; a journal of technical methods and pathology. 2008 Academic Article GET IT
Times cited: 48
Effect of hepatocyte growth factor on methionine adenosyltransferase genes and growth is cell density-dependent in HepG2 cells. Journal of cellular physiology. 2007 Academic Article GET IT
Times cited: 26
Platelet FcgammaRIIA receptor surface expression is increased in patients with ESRD and is associated with atherosclerotic cardiovascular events. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2007 Academic Article GET IT
Times cited: 5

more ...

less ...

Background

education and training

M.S., Duke University 2018
M.D., University of Aleppo Faculty of Medicine (Syrian Arab Republic) 2002

Contact

full name

Mazen Noureddin

VIVO Weill Cornell Medical College

Mazen Noureddin Clinical Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name